Survival Benefit of Combined Chemoimmunotherapy and Radiation Therapy in Patients with Recurrent or Metastatic Esophageal Cancer
Adding RT can significantly improve survival in patients with recurrent or metastatic esophageal cancer who are treated with chemoimmunotherapy, but further prospective trials are needed for validation.
Authors
- Jiangxue Cheng (ORCID: https://orcid.org/0009-0007-3229-0478)
- Jieyong Tian
- Xueru Wang (ORCID: https://orcid.org/0000-0002-5220-7113)
- Dong Guo (ORCID: https://orcid.org/0000-0001-8067-5531)
- Xiaoyang Li (ORCID: https://orcid.org/0000-0003-3741-3688)
- Dong Qian (ORCID: https://orcid.org/0000-0002-3232-5104)
- Yuan He (ORCID: https://orcid.org/0000-0002-6461-5341)
Institutions
- University of Science and Technology of China (CN)
- Anhui Provincial Hospital (CN)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.adro.2025.101890
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00